Kei Kishimoto

Company: Selecta Biosciences

Job title: Chief Scientific Officer

Seminars:

Increasing the Therapeutic Window of Engineered Interleukin-2 & Driving Expansion of Antigen-Specific Regulatory T cells with ImmTOR Tolerogenic Nanoparticles 12:30 pm

IL-2 can be engineered to increase its half-life and selectivity for Tregs; however, selectivity can be reduced at higher doses and in settings of activated effector cells ImmTOR nanoparticles loaded with rapamycin acts synergistically with engineered IL-2 to increase expansion Tregs while mitigating effector cell activation Engineered IL-2 combined with ImmTOR also acts synergistically to…Read more

day: Day One AM Non-Cell Based Approaches